Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?

• Status: Withdrawn
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: Female

Summary

This study will address the value of adding intralipid infusion in reducing pregnancy complications related to antiphospholipid syndrome

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Antibodies; Antibodies, Antiphospholipid; Aspirin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Soybean oil, phospholipid emulsion

Criteria

Inclusion Criteria:

• Pregnant women at booking date who were already diagnosed to have antiphospholipid syndrome (APS) .

Exclusion Criteria:

• Patients with gestational age ≥ 9 weeks

• patients with diagnosed other auto-immune disorder

• patients with chronic hypertension, diabetes mellitus, thyroid disorders,

• patient with renal diseases

• patients who requested to withdraw from the study at any point .